Inhibikase Therapeutics (NASDAQ: IKT) shares Q2 2025 results and investor presentation

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. filed a current report noting that it has announced its financial results for the quarter ended June 30, 2025 and provided other corporate updates through a press release. The press release is furnished as an exhibit and is not treated as part of the company’s formal, liability-bearing SEC filings unless later specifically incorporated by reference.

The company also updated its corporate presentation for use in meetings with investors, analysts and others, and furnished this presentation as a separate exhibit. Both the press release and the presentation are being shared for informational purposes under the Exchange Act without being deemed formally filed.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001750149 0001750149 2025-08-14 2025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39676		26-3407249
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
1000 N. West Street, Suite 1200
Wilmington, DE				19801
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (302) 295-3800

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IKT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure

On August 14, 2025, Inhibikase Therapeutics, Inc. updated its corporate presentation for use in meetings with investors, analysts and others from time to time. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.2 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release issued by Inhibikase Therapeutics, Inc., dated August 14, 2025, furnished herewith.

99.2 Corporate Presentation of Inhibikase Therapeutics, Inc., dated August 14, 2025, furnished herewith.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2025				INHIBIKASE THERAPEUTICS, INC.
				By:		/s/ Mark Iwicki
						Mark Iwicki
						Chief Executive Officer

FAQ

What did Inhibikase Therapeutics (IKT) disclose in this 8-K?

Inhibikase Therapeutics disclosed that it announced financial results for the quarter ended June 30, 2025 and provided other corporate updates via a press release furnished as an exhibit, and that it updated its corporate presentation for investors, which is also furnished as an exhibit.

Which period do the new Inhibikase Therapeutics (IKT) results cover?

The financial results referenced in the report cover the quarter ended June 30, 2025.

How did Inhibikase Therapeutics (IKT) share its quarterly results and updates?

The company shared its quarterly results and other corporate updates through a press release, which is furnished as Exhibit 99.1 to the report.

What is included in Inhibikase Therapeutics’ updated corporate presentation?

The report states that Inhibikase Therapeutics updated its corporate presentation for use in meetings with investors, analysts and others, and furnished this presentation as Exhibit 99.2, though the specific content is not described in the report text.

Are Inhibikase Therapeutics’ press release and presentation considered filed with the SEC?

The company specifies that the information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.

Who signed the Inhibikase Therapeutics (IKT) 8-K current report?

The report was signed on behalf of Inhibikase Therapeutics, Inc. by Mark Iwicki, the company’s Chief Executive Officer.